Regulation FD Disclosure. On February 9, 2026, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that encouraging patient survival data had been observed in its ovarian cancer CAR-T therapy Phase 1 clinical trial and that regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol. The press release is furnished as Exhibit 99.1 hereto Statements that are not historical fact m…

Regulation FD Disclosure. On December 11, 2025, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the Company and The Cleveland Clinic Foundation (“Cleveland Clinic”) presented final data from the Phase 1 clinical trial of its investigational breast cancer vaccine. The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic and co-inventor…

Regulation FD Disclosure. On November 8, 2024, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the Company and The Cleveland Clinic Foundation (“Cleveland Clinic”) presented new, updated positive data for the Phase 1 study of its breast cancer vaccine. The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic. Furnished heret…

Entry Into a Material Definitive Agreement On May 3, 2024, Anixa Biosciences, Inc. (the “ Company ”) and the Cleveland Clinic Foundation (the “ CCF ”) entered into a Joint Development and Option Agreement (the “ Agreement ”). Pursuant to the Agreement, the parties agreed on the terms and conditions under which the parties will collaborate in efforts to develop vaccines for the prevention or treatment of cancers in the Fields. In consideration of its Agreement, the Company will pay CCF a non-r…

Regulation FD Disclosure. On December 6, 2023, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the Company and Cleveland Clinic Foundation (“Cleveland Clinic”) presented new and updated positive data from the Phase 1 study of its breast cancer vaccine. The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by G. Thomas Budd, M.D. of Cleveland Clinic Cancer Institute. Furnished hereto as Exhibi…

Regulation FD Disclosure. On April 17, 2023, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the Company and The Cleveland Clinic Foundation (“Cleveland Clinic”) presented positive data for the Phase 1 study of its breast cancer vaccine. The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by G. Thomas Budd, M.D. of Cleveland Clinic’s Taussig Cancer Institute. Furnished hereto as Exhibit 99.…

Regulation FD Disclosure. On December 8, 2022, Anixa Biosciences, Inc. (“we,” “us,” “our,” or the “Company”) issued a press release announcing that the maximum tolerated dose has been reached in the Phase 1a clinical trial of the Company’s preventative breast cancer vaccine technology that is being developed in collaboration with The Cleveland Clinic Foundation (the “Cleveland Clinic”). The press release, which is furnished as Exhibit 99.1 hereto, was issued following a presentation made by c…

Regulation FD Disclosure. On September 28, 2022, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center and the inventor of Anixa Biosciences, Inc.’s (“we,” “us,” “our,” or the “Company”) chimeric endocrine receptor T-cell technology—a new kind of chimeric antigen receptor T-cell technology (CAR-T)—made a virtual presentation at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium. During Dr.…

President — Michael Catelani: Michael Catelani was promoted to President while retaining his roles as Chief Operating Officer and Chief Financial Officer.

Termination of a Material Definitive Agreement On June 16, 2021, Anixa Biosciences, Inc. (the “Company”) delivered notice to B. Riley FBR, Inc. (the “B. Riley FBR”) terminating the At-the-Market Issuance Sales Agreement, dated June 21, 2019 (the “Agreement”), with B. Riley FBR effective as of June 21, 2021. The Agreement provided for the Company to offer and sell shares of the Company’s common stock from time to time in an at-the-market equity program through B. Riley FBR, as sales agent. SIG…

Director — Dr. John Monahan, David Cavalier: Dr. Monahan and Mr. Cavalier decided not to stand for re-election due to new California legislation on board diversity.

Entry into a Material Definitive Agreement. On March 22, 2021, Anixa Biosciences, Inc. (the “Company”) entered into an amended and restated underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative (the “Representative”) of the underwriters (the “Underwriters”), to issue and sell 4,285,715 shares of common stock of the Company, par value $0.01 per share (“Common Stock”), in an underwritten, firm-commitment public offering pursuant to an effective…

Entry into a Material Definitive Agreement. Reference is made to that certain exclusive license agreement, entered into on November 30, 2020 (the “License Agreement”), between Anixa Biosciences, Inc. (the “Company”) and The Cleveland Clinic Foundation, a nonprofit Ohio corporation (“CCF”), pursuant to which the Company was granted (i) an exclusive worldwide license to certain patents and patent applications (the “Licensed Patents”) pertaining to the use of vaccines for the therapeutic treatme…

Entry into a Material Definitive Agreement. On November 30, 2020, Anixa Biosciences, Inc. (the “Company”) entered into an exclusive license agreement (the “Agreement”) with The Cleveland Clinic Foundation, a nonprofit Ohio corporation (the “Licensor”). Pursuant to the Agreement, the Company has been granted (i) an exclusive worldwide license to certain patents and patent applications (the “Licensed Patents”) pertaining to the use of vaccines for the therapeutic treatment or prevention of ovar…